Quidelortho (QDEL) reported $2.7B in revenue for fiscal 2025, −1.9% year on year. That ranks #1167 by revenue among 2853 SEC filers and #102 in Healthcare. It posted a net loss of −$1.1B for the same year. Revenue has grown 10.4% a year on average since 2020 ($1.7B then). The fiscal 2025 balance sheet shows $5.8B in total assets, $170M in cash and $2.7B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $2.7B | −1.9% | FY20252025-12-28 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$919M | +$1.0B | FY20252025-12-28 |
| Net incomeNetIncomeLoss | −$1.1B | +$920M | FY20252025-12-28 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $105M | +26.7% | FY20252025-12-28 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $188M | −3.5% | FY20252025-12-28 |
| Total assetsAssets | $5.8B | −10.2% | FY20252025-12-28 |
| Shareholders' equityStockholdersEquity | $1.9B | −35.7% | FY20252025-12-28 |
| CashCashAndCashEquivalentsAtCarryingValue | $170M | +72.7% | FY20252025-12-28 |
| Long-term debtLongTermDebt | $2.7B | +8.4% | FY20252025-12-28 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-29 | $620M | −$91.8M | Open → |
| Q2 20262026-06-28 | $631M | −$92.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 158 of 161 companies compared | −41.5% | |
| Operating marginRank 157 of 160 companies compared | −33.7% | |
| R&D as share of revenueRank 57 of 102 companies compared | 6.8% | |
| Cash as share of revenueRank 116 of 160 companies compared | 6.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Quidelortho Corp
- Ticker
- QDEL
- Exchange
- Nasdaq
- SIC classification
- In Vitro & In Vivo Diagnostic Substances (2835)
- Fiscal year end
- 01-01
- CIK
- 0001906324
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Bright Horizons Family SolutionsBFAM | $2.9B | $193M |
| Neurocrine BiosciencesNBIX | $2.9B | $479M |
| Kindercare Learning CompaniesKLC | $2.7B | −$113M |
| QuidelorthoQDEL | $2.7B | −$1.1B |
| Fortrea HoldingsFTRE | $2.7B | −$989M |
| Envista HoldingsNVST | $2.7B | $47.0M |
| InsuletPODD | $2.7B | $247M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Quidelortho — Key figures |url=https://companiesranked.com/en/company/quidelortho |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Quidelortho — Key figures. CompaniesRanked. https://companiesranked.com/en/company/quidelorthoBibTeX
@misc{companiesranked-en-company-quidelortho-2026,
author = {{CompaniesRanked}},
title = {{Quidelortho — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/quidelortho}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001906324-26-000008 · February 19, 2026
{{cite web |title=Quidelortho — Key figures — 10-K (0001906324-26-000008) |url=https://www.sec.gov/Archives/edgar/data/1906324/000190632426000008/qdel-20251228.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.